Emerging pharmacologic therapies for primary sclerosing cholangitis

Research output: Contribution to journalArticle

6 Scopus citations


PURPOSE OF REVIEW: The only currently approved treatment for primary sclerosing cholangitis (PSC) is liver transplantation, with a median time to transplant of 12–18 years after diagnosis. There are a number of emerging drugs that have the potential to meet this critically unmet need that will be summarized and discussed herein. RECENT FINDINGS: Although the cause of PSC is unknown, there are a number of novel therapeutics under development. These drugs target presumed pathogenic mechanisms largely extrapolated from ex-vivo and in-vivo preclinical models, as well as translational observations. SUMMARY: Future therapeutic strategies for PSC may include a multitude of complex pathogenic mechanisms encompassing pathways of immunomodulation, the microbiome and inflammation-related fibrosis.

Original languageEnglish (US)
JournalCurrent Opinion in Gastroenterology
StateAccepted/In press - Mar 2 2017

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Emerging pharmacologic therapies for primary sclerosing cholangitis'. Together they form a unique fingerprint.

  • Cite this